Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 7-8, 2011, Pages 955-961

  Nakamoto, Shingo ^a   Kanda, Tatsuo ^a   Imazeki, Fumio ^a   Wu, Shuang ^a   Arai, Makoto ^a   Fujiwara, Keiichi ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Antiviral treatment; HCV; IL28B; Null virological response; PCRRFLP

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; AFRICA; ALLELE; ANTIVIRAL RESISTANCE; ARTICLE; ASIAN; BLOOD SAMPLING; EUROPE; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIROLOGY;

ADULT; AGED; DNA RESTRICTION ENZYMES; GENETIC TESTING; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 79960202529     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.574731     Document Type: Article

References (22)

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26:34S-8S. (Pubitemid 27388069)
2. Aytaman A, Kaufman M, Terrault NA. Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant 2010;15:301-9.
3. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51. (Pubitemid 44903748)
4. Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, et al. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat 2010; Epub ahead of print.
5. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-33. (Pubitemid 32165347)
6. Xing J, Watkins WS, Witherspoon DJ, Zhang Y, Guthery SL, Thara R, et al. Fine-scaled human genetic structure revealed by SNP microarrays. Genome Res 2009;19:815-25.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis Ctreatment-induced viral clearance. Nature2009;461:399-401.
8. Yokosuka O, Ikeuchi T, Kanda T, Kawai S, Imazeki F, Saisho H, et al. The prevalence of TT virus infection in renal transplant recipients in Brazil. Transplantation 2000; 70:1194-7.
9. Tanaka Y, NishidaN, SugiyamaM,KurosakiM,MatsuuraK, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
10. Rauch A, Kutalik Z, Descombes P, Cai T, Di luio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitisCand treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45.
11. Lindh M, Lagging M, Norkrans G, Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology 2010;139:1794-6.
12. Imazeki F, Yokosuka O, Omata M. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study. Expert Rev Anti Infect Ther 2010;8:497-9.
13. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
14. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;4:548-61.
15. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-51.
16. Nakamoto S, Kanda T, Yonemitsu Y, Arai M, Fujiwara K, Fukai K, et al. Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by realtime amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol 2009;44:872-7.
17. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
18. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52:1888-96.
19. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010;52:33-7.
20. Tillmann HL, Thompson AJ, PatelK,Wiese M, TenckhoffH, NischalkeHD, et al. A polymorphismnear IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010;139:1586-92.
21. Galmozzi E, Menico BD, Rametta R, Dongiovanni P, Fracanzani AL, Benedan L, et al. A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. J Viral Hepat 2010; Epub ahead of print.
22. Akkarathamrongsin S, Sugiyama M, Matsuura K, Kurbanov F, Poovorawan Y, Tanaka Y, et al. High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. Hepatol Res 2010;40:956-62.